Trial Profile

A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bosutinib (Primary) ; Inotuzumab ozogamicin (Primary)
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use

19 Jul 2023 Interventional Study Model has been changed to Parallel from Single Group Assignment, number of treatment arms changed to 4, primary endpoints has been amended.
25 Jun 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
25 Jun 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com